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Abstract
An advanced glycation end products (AGE)/a receptor for AGE (RAGE) axis plays a central role in 
the pathogenesis of diabetic vascular remodeling. This study was conducted to clarify the role of 
RAGE in nondiabetic atherosclerosis. We used the aortic and coronary atherosclerotic lesions of 
Watanabe heritable hyperlipidemic (WHHL) rabbits prone to myocardial infarction (WHHLMI) at 1 
to 14 months. Immunohistochemistry demonstrated the significant expression of RAGE as early 
as at 1 month with the stronger expression at 3 and 7 months, which was remarkably diminished at 
14 months. RAGE expression was concordant with AGE accumulation. The major original sourc-
es of RAGE expression were macrophages and smooth muscle cells in addition to endothelial cells, 
and RAGE expression was distributed in the areas of phospholipid products, a component of oxidized 
LDL and nitrotyrosine. The concentrations of serum AGE did not alter significantly with ag-
ing. These findings suggested the expression of RAGE was induced by hyperlipidemia and oxida-
tive stress independent of diabetes in WHHLMI rabbits. Additionally, our in vitro study showed 
that silencing of RAGE tended to attenuate oxidized-LDL-triggered PAI-1 expression in human cul-
tured macrophages, as well as oxidized-LDL-induced tissue factor expression in peritoneal macro-
phages, suggesting a possible role of RAGE in prothrombogenic molecular regulation. In conclu-
sion, the present study provides in vivo evidence that RAGE plays an integral role in the initiation 
and progression of nondiabetic atherosclerosis, suggesting that RAGE may be a novel target for 
treating not only diabetic but also nondiabetic vascular complications. 
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Introduction
Major risk factors such as diabetes, hyperlipid-
emia and hypertension are recognized to increase 
atherothrombotic disorders. Especially, diabetes 
increases the morbidity and mortality of cardiovas-
cular diseases1,2). There is increasing evidence that 
inflammation, thrombogenicity and proteolysis are 
associated with the progression and instability of 
atherosclerotic plaques in diabetes3-6). Several me-
diators such as monocyte chemoattractant protein-1 
(MCP-1), plasminogen activator inhibitor 1 (PAI-1), 
tissue factor (TF) and matrix metalloproteinase-9 
(MMP-9) have been shown to contribute to the pro-
cess of diabetic vascular complications3-6). Hyper-
lipidemia is also a well-known risk factor for cardio-
vascular diseases, and lipid-lowering therapy has 
been shown to prevent the risk of cardiovascular 
diseases6,7). A hyperlipidemia-dependent athero-
sclerotic animal model, Watanabe heritable hyperlip-
idemic (WHHL) rabbits prone to myocardial infarc-
tion (WHHLMI), has been employed for the research 
of hyperlipidemic atherosclerosis8). 
Advanced glycation end products (AGE) are 
nonenzymatically glycated and oxidized modifiers of 
proteins and lipids9). Activation of a major receptor 
of AGE (RAGE) enhances inflammatory cell infiltra-
tion including macrophages and T cells and oxidant 
stress, and an AGE/RAGE axis plays a central role 
in the pathogenesis of diabetic vascular complica-
tions10,11). However, it remains to be elucidated 
whether RAGE mediates vascular responses in non-
diabetic atherosclerosis associated with hyperlipid-
emia 
In this study, we attempted to clarify the role of 
RAGE in hyperlipidemia-dependent atherosclerosis 
using WHHLMI rabbits. Furthermore, the effect of 
the knockdown of RAGE on atherosclerosis-related 
molecular expression was investigated in human 
monocyte-derived macrophages and RAGE−/−
mouse peritoneal macrophages. 
Materials and Methods
Animals
Male and female WHHLMI rabbits with no sex-
related differences in atherosclerosis at 1 to 14 
months were bred at the Institute for Experimental 
Animals, Kobe University Graduate School of Medi-
cine8). New Zealand White (NZW) rabbits were ob-
tained from CLEA Japan Inc. (Tokyo, Japan). The 
animals were kept in rooms equipped with laminar-
flow filters at a temperature of ≈22°C and were fed a 
standard rabbit chow in the Experimental Animal 
Laboratory of Fukushima Medical University8,12). 
The RAGE targeting construct and the generation of 
RAGE−/− mice were described previously13,14). 
C57BL/6J wild-type and RAGE−/− mice were pro-
duced by mating C57BL/6J RAGE+/− mice, weaned 
at age 4-5 weeks and maintained in a temperature-
controlled (22°C) facility in the Osaka City Universi-
ty Graduate School of Medicine. Procedures in this 
study were approved by the animal care and use 
committee at the Osaka City University Graduate 
School of Medicine. The experiments of RAGE−/− 
mice were also approved by the Animal Research 
Committee at Fukushima Medical University. 
Study Protocol of WHHLMI Rabbits
One to 14 month-old rabbits were selected on 
the basis of their serum cholesterol levels, which 
ranged from 13.0 to 18.1 mmol/l, to make the de-
grees of atherosclerosis8,15). Rabbits were anesthe-
tized by an intravenous injection of 50 mg/kg sodium 
pentobarbital. The thoracic aortas and coronary ar-
teries of the rabbits were removed and used for im-
munohistochemical analysis of RAGE and its cellular 
origins in atheromatous plaques. These experi-
ments were carried out under the control of the Ani-
mal Research Committee in accordance with the 
Guidelines on Animal Experiments of Kobe Univer-
sity Graduate School of Medicine and Fukushima 
Medical University, the Japanese Government Ani-
mal Protection and Management Law (No. 105), as 
well as the Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 85-23, revised 1996).
Immunohistochemistry
Immunohistochemical staining was performed 
as previously described8,12). Briefly, rabbits were 
anesthetized and perfused with lactated Ringer’s 
solution and then Bouin’s fixative by use of a perfu-
sion apparatus at a constant pressure of 100 mmHg. 
After perfusion-fixation, the atherosclerotic lesions 
of the aortae and coronary arteries were excised and 
then immersed in Bouin’s fixative for at least 24 
hours. After immersion-fixation, the atheroscle-
rotic lesions of descending thoracic aortae and coro-
nary arteries were embedded in paraffin and cut into 
4-μm-thick section. The sections were used for 
immunohistochemical analysis. Sections were re-
acted at 4°C overnight with monoclonal antibodies 
against rabbit macrophages (RAM11, Dako Cytoma-
tion, Carpinteria, CA) diluted 1 : 100, smooth muscle 
α-actin (1A4, 1 : 100 dilution,  Dako Cytomation) and 
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endothelial cells (CD31, 1 : 100 dilution, Dako Cyto-
mation), phospholipid products, a component of oxi-
dized LDL (ox-LDL) (DLH3)16) diluted 1 : 100, AGE 
(6D12, 1 : 100 dilution, Trans Genic Inc., Kumamo-
to, Japan) and nitrotyrosine (Kamiya Biomedical Co., 
Seattle, WA) diluted 1 : 100, and with polyclonal an-
tibody against RAGE (Millipore, Billerica, MA) di-
luted 1 : 400. A streptavidin-biotinylated horserad-
ish peroxidase system (Nichirei, Tokyo, Japan) was 
used and antibody binding was visualized with 3, 
3´-diaminobenzidine and hydrogen peroxide (DAB 
SUBSTRATE KIT FOR PEROXIDASE, Vector Lab-
oratories, Burlingame, CA).
RAGE Expression and Cellular Components of Ather-
omatous Plaques
We defined the atheromatous lesion between 
endothelial cells and internal elastic laminae of ar-
teries as plaque area under a light microscope at 
magnification ×100 as described previously8,12,15). 
The percent area of RAGE expression was defined 
as the RAGE positive area to the total plaque 
area. In the same way, the percent areas of macro-
phages and smooth muscle cells were defined as the 
RAM11-positive and 1A4-positive area to the total 
plaque area, respectively. Image analysis was per-
formed to quantify the immunoreactive area using 
Image J 1.34 (National Institutes of Health, Bethes-
da, MD). 
Mesurement of Serum AGE Levels in WHHLMI Rab-
bits
The level of serum AGE was measured using 
ELISA as described previously17). Briefly, a 96-well 
microtiter plate was coated by overnight incubation 
at 4°C with monoclonal antibody, which detects non-
carboxymethyllysine (CML) AGE. Then 100 μl of 
rabbit serum was added to each well and incubated 
for 2 hours at room temperature with gentle shaking 
on a horizontal rotary shaker. Immunoreactivity of 
each fraction was read from the calibration curve and 
was expressed as AGE unit (U) per ml, with one 
unit corresponding to the amount of antibody reac-
tive material found in AGE-bovine serum albumin at 
a protein concentration of 1 μg/ml.
Isolation of Peripheral Blood Monocytes and Culture of 
Monocyte-Derived Macrophages
Human peripheral blood monocytes were iso-
lated by density centrifugation and adherent method 
from normal healthy volunteers and the purity of 
isolated monocytes was greater than 95% as deter-
mined by flow cytometry and cytohistochemistry as 
described previously18,19). Human monocytes were 
plated in collagen type I-coated 6-well plate (BD 
Biosciences, Bedford, MA) and incubated in a hu-
midified incubator at 37°C in RPMI 1640 medium 
containing 10% fetal bovine serum (FBS) (Invitro-
gen, Carlsbad, CA) for up to 30-72 hours to differen-
tiate into macrophages. Cells were more than 90 
% viable as assessed with trypan blue exclusion. 
Ethical approval was obtained from Fukushima Med-
ical University for the study.
Preparation of Oxidized LDL and Lipoprotein Defi-
cient Serum (LPDS)
Oxidized LDL and LPDS were prepared as de-
scribed previously20). Human LDL (density = 
1.019-1.063 g/ml) and LPDS (density > 1.21 g/ml) 
were isolated from serum of fasting normolipidemic 
volunteers by sequential ultracentrifugation. Oxi-
dized LDL was prepared by incubating native LDL 
for 24 hours at 4°C in phosphate-buffered saline 
(PBS) containing 5 μmol/l CuSO4, then extensively 
dialyzed against PBS and sterilized by filtra-
tion. LPDS was dialyzed against saline containing 
20 mmol/l CaCl2 at room temperature and against 
saline to remove CaCl2. Then, the sample was in-
cubated with silicic acid at 37°C for 4 hours, adjusted 
to 50 mg/ml with saline and then sterilized by filtra-
tion for use.
Fluorescent Immunohistochemistry
Monocytes were cultured in type I collagen-
coated chamber slides (BD BioCoatTM, BD Biosci-
ences) with RPMI 1640 medium containing 10% 
FBS for 72 hours. Cytospin sample slides of mono-
cytes were also prepared. Fluorescent immunohis-
tochemistry of RAGE in monocytes and monocyte-
derived macrophages was performed as described 
previously21). The slides were fixed in 4% formal-
dehyde for 60 minutes and were not permeabilized, 
and incubated with anti-RAGE antibody (Millipore) 
for 20 minutes. After three washes in PBS, Alexa-
Fluor 594-conjugated secondary antibody (Molecular 
Probes, Eugene, OR) was reacted. Stained slides 
were stored in the dark until they were analyzed by 
a confocal microscope (Olympus, Tokyo, Japan) with 
argon (488 nm) lasers.
Knockdown of RAGE
RAGE expression was silenced by small inter-
fering RNA (siRNA) 5´-CACUGCAGUCGGAGCU-
AAUGG-3´ (sense strand)22). Monocyte-derived 
macrophages were transfected with double-strand 
siRNA in serum-free medium mixed with lipo-
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fectamine (Invitrogen) according to the manufactur-
er’s instructions. Four hours after transfection, 
monocyte-derived macrophages were incubated in a 
medium containing 2 mg/ml LPDS for 24 hours and 
subsequently stimulated by 50 μg/ml oxidized LDL. 
Alternatively, cells were treated with an irrelevant 
siRNA 5´-GUACCGCACGUCAUUCGCAUC-3´ 
(sense strand) as a negative control.
Western Blotting
The expression of RAGE, PAI-1, TF and 
β-actin was determined by Western blotting as de-
scribed previously23,24). Oxidized LDL (50 μg/ml) 
was added to nearly confluent human monocytes-
derived macrophages in collagen type I-coated 
6-well plates and incubated for 18 hours with or 
without silencing of RAGE by siRNA. The whole 
cells were collected and solubilized with a hypotonic 
lysis buffer and the protein concentrations were 
measured by the Bradford method. Aliquots con-
taining 20 μg of proteins were subjected to SDS/
polyacrylamide gel electrophoresis. For Western 
blotting, we used specific antibodies to RAGE (Santa 
Cruz Biotechnology Inc., CA) diluted 1 : 200, to PAI-
1 (Molecular Innovations, Southfield, MI) diluted 
1 : 1,000, to TF (Santa Cruz Biotechnology) diluted 
1 : 200, and to β-actin (Santa Cruz Biotechnology) 
diluted 1 : 2,000. The signals from immunoreactive 
bands were visualized by an Amersham ECL system 
(Amersham Pharmacia Biotech UK Ltd., Bucking-
hamshire, England). 
Isolation of Mouse Peritoneal Macrophages 
We used RAGE−/− mice and wild-type litter-
mate mice at the age of 7 weeks to isolate peritoneal 
macrophages. RAGE−/− and wild-type mice were 
injected with 2 ml of thioglycollate medium (Becton, 
Dickinson and Company, Sparks, MD) into the peri-
toneal cavities. After 3 days, the mice were sacri-
ficed and injected with 5 ml PBS into peritoneal cav-
ities to collect peritoneal macrophages. Cells were 
cultured with or without 5 μg/ml oxidized LDL for 
18 hours in RPMI 1640 medium containing 2 mg/ml 
lipoprotein deficient bovine calf serum (Biomedical 
Technologies Inc., Stoughton, MA). 
Densitometric Analysis
After scanning blots into a computer (CANON 
Canoscan 8400F, Canon Inc., Tokyo, Japan), the opti-
cal densities of individual immunoblots were ana-
lyzed using Image J 1.34 (National Institutes of 
Health, Bethesda, MD) as described previously23,24).
Statistical Analysis
Statistical analyses were performed using 
ANOVA with Scheffé’s post hoc test and unpaired 
Student’s t-test. A level of P<0.05 was considered 
significant. Data are represented as means±S.D. 
Results
Atheromatous Plaques with Aging
Atheromatous plaques of the aortae of WHHL-
MI rabbits were significantly found as early as at 1 
month and accelerated at 3 through 14 months (Figs. 
1A and 1B). The data also show the infiltration of 
cellular components including macrophages and 
smooth muscle cells (Figs. 1C and 1D). However, 
at 14 months, the atheromatous plaques consisted of 
decreased cellular components and increased extra-
cellular fibrous and lipid components compared to 7 
months (Figs. 1C and 1D), which was consistent 
with the previous report15). 
RAGE expression
The expression of RAGE was noted as early as 
at 1 month in hyperlipidemia-dependent atheroscle-
rotic lesions and progressively increased at 3 and 7 
months (Fig. 2A), and the intensive expression of 
RAGE in the aortae of 3 months of WHHLMI rabbits 
as determined by Western blotting (Fig. 2B). How-
ever, the atherosclerotic plaques at 14 months had 
the decreased expression of RAGE compared with 7 
months (Figs. 2C and 2D). 
RAGE, AGE and Cellular Component Expression
Fig. 3 shows the cellular components and the 
expression of RAGE, AGE and phospholipid prod-
ucts at 7 months in the atheromatous plaques by im-
munohistochemistry. The expression of RAGE ap-
peared to be distributed in the areas of cellular 
components including endothelial cells, smooth 
muscle cells and macrophages. In addition, RAGE 
and macrophage were distributed in phospholipid 
products expressing area. Interestingly, AGE and 
RAGE were accumulated in nondiabetic hyperlipid-
emia-dependent atheromatous plaques. 
RAGE Expression in Coronary Atheromatous Plaques
The components of coronary atheromatous 
plaques and the original sources of RAGE were sim-
ilar to those of aortic plaques at 7 months. The 
abundant infiltration of macrophages and smooth 
muscle cells were found in the coronary atheroscle-
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rotic lesions. RAGE expression was identified as 
the cellular sources of macrophages and smooth 
muscle cells in addition to endothelial cells (Figs. 
4A, 4B and 4C). The data also show the quantita-
tive analysis of the area of coronary atheromatous 
plaques (Fig. 4D), and RAGE expression (Fig. 4E) 
and its cellular sources with aging (Figs. 4F and 
4G). RAGE expression was progressively in-
creased with aging up to 7 months and markedly de-
creased at the age of 14 months, which was consis-
tent with the extent of cellular infiltration.
Serum AGE Levels
Fig. 5A demonstrated the serum AGE levels at 
2, 4, 8 and 15 months of WHHLMI rabbits, indicat-
ing no significant difference in the serum AGE lev-
els among the four groups. Fig. 5B shows the se-
rum AGE levels of WHHLMI rabbits and control 
NZW rabbits at 4 months. There was no significant 
difference between two groups. The results sug-
gested that the expression of RAGE in hyperlipid-
emia-dependent atherosclerotic lesions was not re-
lated to the serum AGE levels.
AGE Accumulation and Nitrotyrosine Expression with 
Aging
Fig. 6A shows that the deposition of AGE was 
increased with aging and that AGE was predomi-
nantly recognized at the cellular components infil-
trating into atheromatous plaques in WHHLMI rab-
bit aortae. The deposition of AGE was noted at 
endothelial cells as early as at 1 month. The whole 
expression of AGE was increased with aging at 3 and 
7 months, and diminished at the age of 14 months. 
Moreover, immunohistochemistry demonstrated the 
expression of indirect oxidant marker nitrotyrosine 
with aging25), which was similar to AGE deposition 
(Fig. 6B). The data suggested that AGE were pro-
Fig. 1. Quantitative analysis of the absolute plaque areas (A) and proportions (B) of aortic plaques of WHHLMI rab-
bits with aging (1, 3, 7 and 14 months, n=4 to 6), as well as % area of macrophages (C) and smooth muscle cells 
(D). The proportions of plaques were determined by the control values at 1 month (B). Measured values are 
expressed as mean±S.D. *P<0.05. Mo, months and NS, not significant.
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duced by oxidative stress and that the profiles of 
AGE accumulation and nitrotyrosine expression 
were similar to RAGE expression. 
Role of RAGE in Atherosclerosis-Related Molecular 
Expression
Fluorescent immunohistochemistry revealed 
the expression of RAGE on plasma membrane both 
of human monocytes and monocyte-derived macro-
phages (Figs. 7A and 7B). RAGE expression was 
strongly identified in macrophages cultured for 72 
hours rather than for 24 hours by Western blotting 
(Fig. 7C), suggesting that RAGE expression was in-
creased by the differentiation into macrophages. 
Fig. 7D shows that oxidized LDL increased the ex-
pression of RAGE and PAI-1 in human monocyte-
derived macrophages. The silencing of RAGE in 
the macrophages tented to block PAI-1 expression.
In addition, oxidized LDL promoted RAGE and 
TF expression significantly in peritoneal macro-
phages from wild mice. The knockout of RAGE 
tented to decrease oxidized-induced TF expression 
in peritoneal macrophages from RAGE−/− mice 
(Fig. 8).
Discussion
We show here that RAGE expression was asso-
ciated with the initiation and progression of athero-
sclerosis in WHHLMI rabbits, as well as the RAGE-
mediated atherosclerosis-related molecular 
expression.
The present study clearly shows that RAGE ex-
pression is concordant with cellular infiltration of 
macrophages and smooth muscle cells in the athero-
sclerotic lesions of nondiabetic WHHLMI rab-
bits. This is consistent with the previous reports on 
nondiabetic human and animal atherosclerotic le-
sions11,26). AGE are shown to be generated by oxida-
tive stress, and Calkin et al. reported that administra-
tion of antioxidant attenuated the AGE accumulation 
in mice9,27-29). Our data demonstrated that AGE was 
distributed in the areas of  phospholipid products and 
nitrotyrosine in the atherosclerotic lesions. The 
present study suggested that hyperlipidemia trig-
gered-oxidative stress may accelerate AGE genera-
Fig. 2. The expression of RAGE in the aortic atherosclerotic plaques of WHHLMI rabbits with aging by immunohis-
tochemistry (A) and Western blotting (B). A : RAGE expression at 1, 3, 7 and 14 months. B : Western blot-
ting of RAGE in the aortae of 3-month-WHHLMI rabbits. Immunoblot was probed with a specific goat anti-
RAGE antibody (lane 2), whereas nonimmunized normal goat IgG was used as a negative control antibody (lane 
1). RAGE was identified at the band of 46 kD in the atherosclerotic lesions of 3-month-WHHLMI rabbit. C 
and D : Quantitative analysis of RAGE expression of area (C) and proportion (D) in the atherosclerotic plaques of 
WHHLMI rabbits at 1, 3, 7 and 14 months (n=4 to 6, each month). Measured values are represented as 
mean±S.D. *P<0.05.
115RAGE in nondiabetic atherosclerosis
tion and RAGE expression in cellular compo-
nents29-31), especially macrophages in the nondiabetic 
atherosclerosis. 
It is well acknowledged that atheromatous 
RAGE expression is accelerated with high plasma 
glucose levels and stronger in diabetics than nondia-
betics5,26). Soro-Paavonen et al. have shown that 
knockout of RAGE attenuates the development of 
atherosclerosis in diabetic mice10). These suggested 
a central role of RAGE in the atherosclerosis compli-
cated with diabetes. In addition, several studies 
have suggested that RAGE expression is involved in 
inflammatory cell infiltration, thrombogenicity and 
plaque destability through various signaling pathways 
in diabetic and nondiabetic atherosclerotic le-
sions32-36). Harja et al. have demonstrated that endo-
thelial RAGE modulates vascular and inflammatory 
responses independent of diabetes in apoE−/− mice, 
suggesting the important role of RAGE in the patho-
genesis of nondiabetic atherosclerosis11).
We demonstrated that the significant expres-
sion of RAGE was recognized in endothelial cells as 
early as at 1 month in the aortic atherosclerotic le-
sions of WHHLMI rabbits, as well as at 3 and 7 
months. This finding concurred with the results 
reported by Roy et al. that RAGE is expressed in the 
endothelial cells of the aortic atherosclerotic lesions 
of diabetic 2-month-WHHL rabbits37). 
The glucose metabolism in WHHLMI rabbits is 
a critical issue in this study, which was extensively 
investigated in adult (10- to 15-month-old) and mid-
dle-aged (17- to 21-month-old) WHHLMI rab-
bits38). Briefly, changes in blood sugar levels were 
similar among the three groups, adult normal and 
WHHIMI rabbits and middle-aged WHHIMI rab-
bits. In terms of glucose tolerance, there were two 
groups in both adult and middle-aged WHHLMI rab-
bits. The rabbits with high fasting immunoreactive 
insulin (IRI) levels showed insulin resistance as de-
termined by HOMA-R and Matsuda-insulin sensi-
tivity index (ISI). However, overall, there was no 
significant difference in glucose tolerance among the 
three groups (normal adult rabbits, and adult and 
middle-aged WHHIMI rabbits). Also, we have the 
Fig. 3. Immunohistochemistry of the aortic atherosclerotic plaques of 7-month-WHHLMI rabbits. Results were 
from one representative out of four 7-month-WHHLMI rabbits. Immunostainings for endothelial cells (CD31), 
smooth muscle α-actin (1A4), AGE, RAGE, macrophages (RAM-11),  phospholipid products (DLH3) and RAGE 
and AGE are shown. 
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data regarding the glucose metabolism including 
fasting blood sugar levels, IRI concentrations and 
HOMA-R in 6-month, 12-month and 18-month-old 
WHHIMI rabbits, demonstrating that the changes in 
glucose metabolism are similar among the three 
groups (unpublished data).
Endothelial dysfunction accelerates the devel-
opment of atherosclerosis including monocyte che-
motaxis, monocytes adhesion to endothelial cells 
and proteolysis19,23,39). Moreover, MCP-1, vascular 
cell adhesion molecule-1 (VCAM-1) and MMP-2 are 
modulated by RAGE in endothelial cells under non-
diabetic conditions11). Taken together, our results 
regarding strong expression of RAGE in endothelial 
Fig. 4. A, B, C : RAGE expression (A) and cellular components including macrophages (B) and smooth muscle cells 
(C) in coronary atherosclerotic plaques of 7-month-WHHLMI rabbits as determined by immunohistochemis-
try. Results were the representative sections of the coronary atheromatous lesions from 5 rabbits of 7-month-
WHHLMI. D, E, F, G : Quantitative analyses of the amounts of plaques (D), and the proportion of RAGE ex-
pression (E) and cellular components including macrophages (F) and smooth muscle cells (G) in coronary plaques 
of WHHLMI rabbits with aging (1, 3, 7 and 14 months, n=5 to 6). Values are represented as mean±S.D.    
*P<0.05.
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cells suggested that endothelial RAGE may initiate 
and accelerate nondiabetic atherosclerosis indepen-
dent of diabetes.
In the present study, we showed that RAGE ex-
pression was accelerated with cellular infiltration 
and that the atherosclerotic lesions with reduced 
cellular components at 14 months had marked de-
crease in RAGE expression. However, we found 
no significant difference in the serum AGE levels 
with aging, as well as between WHHLMI rabbits and 
Fig. 5. A : The serum AGE levels of WHHLMI rabbits with aging (2, 4, 8 and 15 months, n=4 to 5). B : The se-
rum AGE levels of WHHLMI rabbits (n=4) and NZW rabbits (n=5) at 4 months. Data are expressed as 
mean±S.D.
Fig. 6. AGE accumulation (A) and nitrotyrosine expression (B) in aortic atherosclerotic plaques with aging as deter-
mined by immunohistochemistry. Results were the representative sections of the aortic atheromatous lesions 
from 1, 3, 7 and 14 months of WHHLMI rabbits.
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normal NZW rabbits. These results suggested that 
serum AGE levels were not a determinant of RAGE 
expression in atherosclerotic lesions.
We attempted to clarify the issue what regu-
lates RAGE expression in nondiabetic atheromatous 
plaques. Since Oka et al. reported that the plasma 
cholesterol and oxidized LDL levels are markedly 
high as early as 1 month with the persistent high 
levels in WHHL rabbits40), one possibility may be 
hyperlipidemia which impairs endothelial function 
and accumulates macrophages in plaques39). Al-
though Roy et al. found RAGE expression in athero-
sclerotic lesions of diabetic WHHL rabbits37), we 
demonstrated the expression of RAGE in endothelial 
cells and macrophages of pure hyperlipidemia-de-
pendent atherosclerotic animal model independent 
of diabetes. Our in vitro study demonstrated that 
oxidized LDL increased RAGE expression in macro-
Fig. 7. A : Immunofluorescent detection of RAGE in human circulating monocytes (upper left panel, specific anti-
RAGE antibody ; upper right panel, phase contrast ; lower left panel, non immunized normal goat IgG ; lower 
right panel, phase contrast). B : Immunofluorescent detection of RAGE in monocyte-derived macrophages cul-
tured for 72 hours (upper left panel, specific anti-RAGE antibody ; upper right panel, phase contrast ; lower left 
panel, non immunized normal goat IgG ; lower right panel, phase contrast). C : The expression of RAGE was 
determined by Western blotting after 24 and 72 hours of culture. D : Effects of knockdown of RAGE on oxi-
dized LDL-triggered PAI-1 expression in cultured macrophages. Isolated monocytes were incubated for 18 
hours in the presence or absence of 50 µg/ml oxidized LDL after transfection of RAGE siRNA or scrambled siR-
NA. PAI-1 expression was determined by Western blotting. Immunoblots are from one experiment represen-
tative from three separate experiments.
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phages. These findings suggest the regulation of 
RAGE expression by hyperlipidemia and oxidized 
LDL.
Another possibility of the mechanism of RAGE 
expression in nondiabetic athrosclerotic lesions may 
be oxidative stress28), which nonenzymatically gen-
erates AGE. It has been shown that statin sup-
presses RAGE expression by decreasing oxidant 
stress-dependent AGE generation in human diabetic 
atherosclerotic plaques36). Statin has been also re-
ported to attenuate RAGE expression probably via 
decreased oxidant stress in the absence of lipid-low-
ering effect29,41). In the present study, RAGE ex-
pression and AGE accumulation were associated 
with nitrotyrosine expression with cellular infiltra-
tion in the atherosclerotic lesions. This finding 
suggested that the accumulation of peroxynitrate-
mediated protein oxidation reflected hyperlipidemia-
dependent oxidative stress, which may induce AGE 
accumulation and RAGE expression in plaques.
Burke et al. have suggested that RAGE expres-
sion may be involved in the plaque instability in dia-
betes since stronger RAGE expression in plaques 
was found in sudden death diabetic subjects than 
nondiabetics26). Our study using WHHLMI rabbits 
suggested the possibility that the intensive expres-
sion of RAGE in endothelial cells and macrophages 
of coronary atherosclerotic lesions may contribute to 
inflammation, thrombogenicity and extracellular ma-
trix degradation in plaques, in turn, plaque destabili-
zation. Further study is required for a better un-
derstanding of the mechanism by which RAGE 
signaling leads to plaque instability.
In conclusion, we show that RAGE may play an 
integral role in the pathogenesis of atherosclerosis 
in WHHLMI rabbits independent of diabetes, sug-
gesting that RAGE may be a good target to treat dia-
betic and nondiabetic vascular complications. 
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